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A B S T R A C T
Breast cancer chemotherapy can cause side effects due to nonspecific drug delivery, low solubility and fast
metabolism of drugs used in conventional therapy. Moreover, the therapeutic effect of the drugs is often reduced
by the strengthening of chemoresistance, which occurs via a variety of mechanisms. Different strategies have
been developed to reduce multidrug resistance (MDR)-associated gene expressions including the use of surfac-
tants and polymers. In this study superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with
conjugated linoleic acid (CLA) reduced the number and viability of cells in comparison with both untreated cells
or cells treated with SPIONs alone. This cytostatic effect correlated with the increase of peroxisome proliferator-
activated receptors γ (PPARγ). The necrotic cell death induced, as a consequence, an inflammatory process, as
evidenced by the decrease of the anti-inflammatory PPARα and increase of pro-inflammatory TNFα and IL-1β.
PPARs were examined because CLA is one of their natural ligands. The antitumor effect observed was accom-
panied by a down-regulation of p-glycoprotein (P-gp), which was the first important discovered efflux trans-
porter belonging to MDR, and of ALDH3A1, an enzyme able to metabolize some drugs, reducing their effects.
The down-regulation of P-gp correlated with the increase of cytokines. The ALDH3A1 decrease correlated with
the increase of PPARγ. Based on these results, PPARs are molecular mediators of anti-cancer effect of SPIONs
functionalized with CLA, being changes in these nuclear receptors correlated with induction of cytotoxicity and
inflammation, and decreased ability of cancer cells in blocking anti-cancer drug effect.
1. Introduction
Breast cancer is the most common neoplasm, among all cancer types
affecting females. It represents 25% of all cancer cases and the leading
cause of cancer mortality (15%). The number of those who die of
neoplasms remains high, even if in the last years screening, early di-
agnosis and improved therapeutic protocols contributed to a fall in total
cancer mortality, with a favourable trend also for breast cancer [1].
Conventional chemotherapy for breast cancer can cause severe side
effects due to distribution to off-target tissues [2,3]. Moreover, the
therapeutic potential of these drugs is often reduced by the onset of
chemoresistance that occurs in a variety of distinct mechanisms and
pathways. These include a reduction of intracellular pro-drug activation
and an increased drug inactivation by Phase I and/or II enzymes [4].
In order to overcome the critical aspects of conventional
chemotherapy, new nanotechnology-based approaches are currently
under investigation. In particular, different types of nanocarriers, in-
cluding polymeric nanoparticles, liposomes, micelles and magnetic
nanoparticles were experimentally tested for cancer diagnosis, imaging
and treatment [5]. In particular, superparamagnetic iron oxide nano-
particles (SPIONs) have been proposed for diagnostic assays, for local
hyperthermia-based cancer therapy and intra-tumour delivery of con-
ventional drugs or monoclonal antibodies, viral vectors engineered with
genes or shRNAs [6–8]. Due to the chance of targeting tumor with
SPIONs, their side effects on non-cancerous tissues can be reduced [9].
Physico-chemical and biological properties of SPIONs can be im-
proved through surface modifications, increasing also the nanoparticle
dispersion [10,11]. Our previous study highlighted that SPIONs func-
tionalized with CLA, known for its anticancer properties, have an in-
creased dispersion and a stronger cytotoxic effect on mouse breast
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cancer cells 4T1 in comparison with SPIONs alone [12].
In the present study, the mechanisms underlying the effect of CLA-
functionalized SPIONs (SPIONs + CLA) were investigated. Particular
attention was paid to the type of cell death induced, to the effect on
inflammation process, to the possible involvement of PPARs and to the
effect on P-gp and ALDH3A1 which are involved in cancer chemore-
sistance. PPARs were investigated because CLA is a natural ligand of
these nuclear hormone receptors that regulate the expression of genes
involved in several intracellular signal transduction pathways, in-
cluding proliferation and survival.
2. Materials and methods
2.1. Materials
Unless otherwise specified reagents were purchased from Sigma-
Aldrich, Germany.
2.2. SPION preparation
Synthesis and characterization of SPIONs were carried out as pre-
viously described [12]. In the experiments reported here SPIONs alone
and SPIONs coated with a single layer of CLA, at the highest of the two
amounts that were initially synthetized (4.5 μl CLA/ml of SPION sus-
pension, SPIONs + CLA), were used for cell treatment.
2.3. Cell cultures and treatment of cells with SPIONs
Mouse breast cancer cells 4T1 were seeded (12,500 cells/cm2) in
DMEM/F-12 medium supplemented with 2mM glutamine, 1% (v/v)
antibiotic/antimycotic solution, 10% (v/v) fetal bovine serum (FBS)
and maintained at 37 °C in a humidified atmosphere of 5% CO2 in air.
24 h after cell seeding, culture medium was removed and replaced
with the same amount of medium not supplemented or supplemented
with SPIONs or SPIONs + CLA, both at the concentrations of 8 μg,
16 μg or 32 μg SPION/105 cells. Untreated 4T1 cells were used as
control.
Human lung A427 cells (ATCC, MD, USA) were cultured
(20,000 cells/cm2) in DMEM/F12 medium supplemented with 2mM
glutamine, 1% antibiotic/antimycotic solution and 10% FBS.
Human lung-adenocarcinoma A549 cells were from ATCC
(Rockville, MD, USA) and cultured (25,000 cells/cm2) in HAM F-12K
medium supplemented with 2mM glutamine, 1% antibiotic/anti-
mycotic solution, 1% non-essential amino acids and 10% (v/v) FBS.
24 h after cell seeding, culture medium was removed and replaced
with the same amount of medium not supplemented or supplemented
with SPIONs or SPIONs + CLA 16 μg SPION/105 cells.
2.4. Cell growth and viability
At the different experimental times (12, 24, 48 or 72 h) 4T1 ad-
herent cells were detached by trypsin/EDTA (0.5%/0.03 mM), and
culture media were collected. Aliquots of both adherent cells and cul-
ture medium were used for counting cells by flow cytometry analysis.
Remaining cells and culture medium were combined, centrifuged at
400 g at 4 °C for 5min, washed with PBS, and resuspended in Annexin-
binding buffer (0.5× 106 cells/ml) in order to evaluate the percentage
of viable, necrotic or apoptotic cells by flow cytometry (Annexin
V–FITC Apoptosis Detection Kit, eBioscience, CA). Briefly, 195 μl of cell
suspension were added with 5 μl of Annexin V-FITC and incubated at
room temperature for 10min. Then, cells were washed with 200 μl of
binding buffer (1X), resuspended in 190 μl of the same buffer, and
added with 10 μl (20 μg/ml) of propidium iodide. Samples were ana-
lysed (20,000 events) by flow cytometry (BD Accurri C6, BD
Biosciences, CA).
A549 and A427 cells were detached by trypsin/EDTA (0.5%/
0.03mM) at 72 h and used for growth evaluation only.
2.5. Inhibition of PPARγ by antagonist GW9662
Mouse breast cancer cells 4T1 treated as reported in section 2.3
were also supplemented with 10 μM GW9662, a well known PPARγ
antagonist. In these experiments the following groups were analysed: C,
untreated cells; C + Gw9662, untreated cells exposed to 10 μM
GW9662; M, cells treated with SPIONs (16 μg/105 cells); M+ GW9662,
cells treated with SPIONs (16 μg/105 cells) + 10 μM GW9662;
M + CLA, cells treated with SPIONs + CLA (16 μg/105 cells);
M + CLA + GW9662, cells treated with SPIONs + CLA (16 μg/
105 cells) + 10 μM GW9662. GW9862 was added to cell cultures si-
multaneously with SPIONs. The evaluation of cell growth was carried
out at 24 and 48 h treatment.
2.6. Western blot and real-time PCR analyses
Proteins and total RNA were isolated from 4T1 cells using the Tri-
Reagent Kit according to the manufacturer's protocol.
35 μg of proteins were separated by SDS–polyacrylamide gel elec-
trophoresis and electro-transferred to a polyvinylidene difluoride
(PVDF) membrane (Thermo Fisher Scientific, MA), which was then
blocked for 1 h with TBS containing 5% non-fat dry milk. The mem-
brane was then rinsed and incubated overnight with polyclonal anti-
PPARα or anti-PPARγ antibodies (Santa-Cruz Biotechnology Inc., CA)
and monoclonal anti-β-actin antibodies. Protein bands were visualized
using a chemiluminescent detection system (Pierce® ECL Plus Western
Blotting Substrate, Thermo Scientific, IL).
1 μg of total RNA was reverse transcribed to cDNA using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, CA).
16 μl of a PCR mixture containing 2 μl of cDNA template, 5 pmoles each
of forward and reverse primers (Table 1), bidistilled water and the
Power SYBR® Green PCR Master Mix (Applied Biosystems, CA) were
amplified using an iCycler PCR instrument (Bio-Rad, CA) with an initial
denaturation at 95 °C for 10min, followed by 35–40 cycles at 95 °C for
30 s, annealing at 52 °C for 40 s, extension at 72 °C for 40 s. Each sample
was tested in duplicate and threshold cycle (Ct) values were averaged
out from each reaction. The change in expression was defined as that
detected in the treated 4T1 cells versus that detected in the untreated
cells, calculated as 2−ΔΔCt, where ΔCt=Ctsample-CtGAPDH and
ΔΔCt= ΔCtsample-ΔCtcontrol.
2.7. Protein content determination
Protein content was measured using the DCTM Protein Assay Kit,
following the manufacturer's instructions (Bio-Rad Laboratories Inc.,
CA).
2.8. Pro-inflammatory cytokine protein content
TNFα and IL-1β content was evaluated in the culture medium by
Enzyme Linked Immuno Sorbent Assay (Invitrogen Corporation,
Frederick, MD).
Table 1
Oligonucleotide primers used in real time PCR.
Genes Forward primers (5′-3′) Reverse primers (5′-3′)
ALDH3A1 TGAGTTAAAGGCATCACGGG GAAAGGCTGAGACTTGCGTC
P-gp TCAAACTTCTGCTCCCGAGT CCAAGCCTTGAAGGACAAGA
TNFα CCAAGGGATGAGAAGTTCC CTCCACTTGGTGGTTTGCTA
IL-1β TCAGGCAGGCAGTATCACTC AGGATGGGCTCTTCTTCAA
PPARγ GCCCTTTGGTGACTTTATGGA GCAGCAGGTTGTCTTGGATG
GAPDH GTCGGAGTCAACGGATTTGG GGGTGGAATCATATTGGAACATG
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2.9. Statistical analysis
All data were expressed as means ± SD. Differences between group
means were assessed by analysis of variance followed by the post hoc
Newman–Keuls test.
3. Results
Mouse breast cancer 4T1 cells were exposed to 8, 16 or 32 μg/
105 cells of SPIONs or SPIONs + CLA and the variations in cell number
were recorded for up to 72 h as reported in Fig. 1. All the concentrations
of both types of nanoparticles caused a reduction of cell number in
comparison with control cells. Regarding the two treatments, the big-
gest effect was observed in presence of SPIONs + CLA. The reduction of
cell number with this SPIONs was dose-dependent until 48 h after the
treatment, reaching the major reduction at 48 h with 32 μg/105 cells
(55.2%). Results at 72 h evidenced that the numbers of cells were si-
milar to those observed at 48 h for 8 and 16 μg/105 cells, whereas for 32
μg/105 cells a growth recovery was observed.
The flow cytometry analysis of viability and of type of cell death is
reported in Fig. 2. The results evidenced that both treatments induced
necrosis and a few apoptosis, but the cytotoxic effect induced by
SPIONs + CLA was bigger. The cytotoxic effect is dose-dependent until
48 h of treatment, whereas at 72 h the cells were more viable than after
48 h, being the increase of viable cells about 11% in presence of
SPIONs + CLA 8 and 16 μg/105 cells and 18% in case of SPIONs + CLA
32 μg/105 cells. It is important to underline that functionalization with
CLA increased the cytotoxic effect of SPIONs alone of about 100%.
Table 2 reports data relative to the effect of SPIONs functionalized
or not with CLA on human lung cancer cells A549 and A427, showing
that CLA presence induced a higher inhibition of cell growth in more
malignant A427 cells than in less malignant A549.
Since CLA is a ligand of PPARs, as other polyunsaturated fatty acids,
PPARγ protein content was evaluated. Fig. 3 shows an increase of
PPARγ at 24 h in cells treated with both SPIONs in comparison with the
control cells, the increase being bigger in cells treated with
SPIONs + CLA and consistent with the reduction of cell number and
cell toxicity.
The involvement of PPARγ in reducing 4T1 cell growth has been
investigated using GW9662, a well known antagonist of this nuclear
receptor. Results reported in Table 3 evidenced that the inhibition of
PPARγ by GW9662 always increased the cell numbers, being the major
recovery present in case of SPIONs + CLA.
The presence of cell necrosis suggested to evaluate some in-
flammation-related parameters: PPARα, TNFα and IL-1β at the ex-
perimental time of 72 h. Fig. 4 shows that PPARα protein content de-
creased with both types of SPIONs and, again, the highest decrease was
observed in cells treated with SPIONs + CLA in comparison with
SPIONs alone and control cells. The decrease of PPARα was accom-
panied by the increase of cytokine protein content, like other para-
meters examined, i.e. there was a bigger increase in cells treated with
SPIONs + CLA in comparison with SPIONs alone and control cells.
P-gp and ALDH3A1 were evaluated in order to investigate the effect
of these types of SPIONs on the mechanism involved in cancer che-
moresistance. Fig. 5 shows a decrease of P-gp and ALDH3A1 in 4T1
cells treated with both types of SPIONs, being SPIONs + CLA the most
efficient in the decrease.
4. Discussion
In a previous study we evidenced that SPIONs functionalized with
CLA affected viability of 4T1 breast cancer cells, being the effect ob-
served bigger if compared to SPIONs alone. This effect is due to the
increased colloidal stability and the anti-cancer properties of the CLA
[13].
In this study we investigated the molecular pathways triggered by
SPIONs + CLA, paying particular attention to the effect on cell pro-
liferation and cell death. Moreover, to confirm the ability of SPIONs in
reducing cancer cell growth, their effect has been investigated in a
preliminary way in human lung cancer cells. The flow cytometry ana-
lysis on 4T1 breast cancer cells evidenced that the decreased cell via-
bility was mainly due to the induction of necrotic cell death, while the
percentage of the apoptotic cells was close to 0%. The decreased effi-
cacy of SPIONs + CLA in reducing cell growth observed at 72 h could
be the consequence of CLA intracellular metabolism, leading to a de-
crease of intracellular free CLA able to trigger signal transduction
pathways.
Interestingly, results on human lung cancer cells seemed to indicate
that SPIONs + CLA show a major effect on more malignant cell line.
The decreased cell number seems negatively correlated with the
increased level of PPARγ after 24 h from treatment. This result agrees
with what observed in different tumour cell lines treated with CLA,
where the decreased cell proliferation associated with the increase of
PPARγ level [14]. With regard to the present study, the pivotal role
played by this nuclear receptor in modulating SPIONs cytostatic effect
has been evidenced by the observation that the antagonist GW9662
completely reversed the decrease of cell number. Moreover, the in-
creased cell number occurring in control cells treated with GW9662
alone further confirm the inverse correlation between PPARγ and pro-
liferation.
Concerning the absence of the apoptotic process, this may partially
be the consequence of the non-increasing PPARα levels. In fact, a pre-
vious study with SK-HEP-1 cells, a human hepatocarcinatoma cell line,
showed that CLA-induced apoptosis was associated with an increase in
PPARα protein. Meanwhile in MDA-MB-231, a human breast cancer cell
line, the CLA-induced inhibition of cell proliferation was not associated
with apoptosis and was not accompanied by an increased content of
PPARα protein [14,15].
The evident necrotic process focused our attention on the resulting
inflammation induction. The analysis of some of the parameters in-
volved in the inflammatory process evidenced an increase in pro-in-
flammatory cytokines TNFα and IL-1β. This increase inversely
Fig. 1. Number of mouse breast cancer 4T1 cells untreated or treated with
SPIONs functionalized or not with CLA.
The number of cells is expressed as percentage of untreated cells set equal to
100 %. The values are means ± S.D. of 4 experiments. For each group (SPIONs
or SPIONs + CLA) means with different letters are significantly different from
one another (p < 0.05) as determined by analysis of variance followed by a
post-hoc Newman-Keuls test.
SPIONs: cells treated with superparamagnetic iron oxide nanoparticles;
SPIONs + CLA: cells treated with superparamagnetic iron oxide nanoparticles
functionalized with conjugated linoleic acid; CLA: conjugated linoleic acid; C:
untreated cells (black line); 8 μg, 16 μg, 32 μg quantity of various SPIONs added
to 100,000 cells.
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correlates with the decreased level of PPARα. These results confirm
what was previously seen in human lung adenocarcinoma A427 cells
treated with CLA [16].
An important characteristic of tumor cells is their ability to block
the effect of drugs, developing resistance by different mechanisms. One
possibility is represented by the alterations of the efflux transporters
such as P-gp [17], while, another one, is to metabolize the drug, making
it inactive.
The acquired resistance to drugs (MDR) could be due to copy
number alterations or increased expression of different genes [16] and
is an important impediment for successful chemotherapy [18,19]. The
most important and well-studied MDR-genes are: ABCB 1 that encodes
the P-glycoprotein (P-gp), the multidrug resistance protein 1 (MDR1),
ABCC 1–3 that encodes the multi-drug resistance associated protein
Fig. 2. Viability of mouse breast cancer 4T1 cells untreated or treated with SPIONs functionalized or not with CLA.
Data are means ± S.D. of 4 experiments and indicate the percentage of cells that are viable, in apoptosis or in necrosis vs. the total number of cells analyzed by flow
cytometry, taken as 100%. SD, not reported, is less than 10% in all cases. For each experimental time analyzed (12, 24, 48 or 72 h), means with different letters are
significantly different from one another (p < 0.05) as determined by analysis of variance followed by a post-hoc Newman-Keuls test.
SPIONS: cells treated with superparamagnetic iron oxide nanoparticles; SPIONs + CLA: cells treated with superparamagnetic iron oxide nanoparticles functionalized
with conjugated linoleic acid; CLA: conjugated linoleic acid; C: untreated cells; 8 μg, 16 μg, 32 μg: quantity of various SPIONs added to 100,000 cells.
Table 2
Number of human lung cancer cells untreated or treated with SPIONs func-
tionalized or not with CLA.
CELLS SPIONs SPIONs + CLA
A549 98.2 83.1
A427 74.4 42.3
The number of cells is expressed as percentage of untreated cells set equal to
100%. The values are means of 2 experiments.
Cells were treated with 16 μg/100,000 cells for 72 h.
Fig. 3. PPARγ protein content in mouse breast cancer 4T1 cells untreated or treated with SPIONs functionalized or not with CLA.
The protein content was determined by Western blot analysis. Band intensities were normalized to the corresponding β-actin value and expressed as a percentage,
setting the value of untreated cells (C) arbitrarily at 100%. Data are means ± S.D. of 4 experiments. For each experimental time considered (24 or 72 h), means with
different letters are significantly different from one another (p < 0.05) as determined by analysis of variance followed by a post-hoc Newman-Keuls test.
See legend in Fig. 2 for acronyms.
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(MRP) 1–3 and ABCG 2 encoding the breast cancer resistance protein
(BCRP). Different strategies were developed to reduce MDR-associated
gene expressions including the use of surfactants that inhibit the drug-
efflux and polymers for their ability to improve the intracellular
transport of chemotherapeutics [16]. Recently, different studies have
evaluated the capability of various nanoparticle formulation in over-
coming MDR in breast cancer, showing that drugs encapsulated by
nanomaterials enter the cancer cells through different mechanisms
overcoming the drug transporters and reversing MDR [17].
P-gp was one of the first efflux transporter discovered [20–22]; it
provides, in physiological conditions, protection from xenobiotics
during brain development and it was highlighted to be up-regulated by
glucocorticoids and inhibited by pro-inflammatory cytokines [22]. In
different “in vivo” and “in vitro” liver and colon tumor models TNFα
downregulated ABCB 1 expression, causing a reduction of drug efflux
and an increase of cytotoxicity [23,24]. This correlation was confirmed
also in this study where the functionalization with CLA increased the
production of TNFα and IL-1β and decreased the expression of P-gp in
comparison with control cells and cells treated with SPIONs alone.
The ability of cancer cells to block the effect of drugs is also due to
the increased expression of ALDH3A1. SPIONs + CLA reduced the ex-
pression of ALDH3A1 through the increase of PPARγ. This inverse
correlation between ALDH3A1 and PPARγ was shown in our previous
study on human lung tumor A549 cells where the ALDH3A1 expression
was decreased by arachidonic acid, another ligand of PPARs, via the
activation of PPARγ and the consequent inhibition of NF-κB transcrip-
tional activity. In fact, ALDH3A1 gene possesses several NF-κB binding
sites [25,26] which are involved in the positive and negative regulation
of its expression [27].
5. Conclusions
This research demonstrated that the SPIONs functionalized with
CLA are able to reduce cell number, induce necrotic cell death and
inflammation in mouse breast 4T1 cells. These effects are mediated by
PPARs: the increase of PPARγ correlated with the decreased cell pro-
liferation and the decrease of PPARα with the increase of pro-in-
flammatory cytokines. In turn, this increase is responsible for the de-
crease of P-gp mRNA level. The increase of PPARγ also correlates with
the decrease of ALDH3A1.
The study results indicate that the anti-cancer properties of SPIONs
functionalized with CLA are mediated by PPARs, being changes in these
nuclear receptors correlated with induction of cytotoxicity and in-
flammation, and decreased ability of cancer cells in blocking anticancer
drug effect.
Table 3
Number of mouse breast cancer 4T1 cells untreated or treated with SPIONs
functionalized or not with CLA (16 μg/105 cells), in presence of PPARγ an-
tagonist GW9662.
TREATMENT 24 h 48 h
% Recovery % Recovery
C 100 100
C + GW9692 114.29 106.10
SPIONs 89.12 80.15
SPIONs + GW9662 100.61 11.49 107.09 26.94
SPIONs + CLA 78.07 58.89
SPIONs + CLA + GW9662 98.69 20.62 100.2 41.31
The number of cells is expressed as percentage of untreated cells set equal to
100%. The values are means ± S.D. of 2 experiments.
Recovery: represents the increase observed in SPIONs + GW9662 in compar-
ison with SPIONs alone, or in SPIONs + CLA + GW9662 in comparison with
SPIONs + CLA alone.
Fig. 4. PPARα, TNFα and IL-1β protein content evaluated after 72 h treatment in mouse breast cancer 4T1 cells untreated or treated with SPIONs functionalized or
not with CLA.
The PPARγ protein content was determined by Western blot analysis. Band intensities were normalized to the corresponding β-actin value and expressed as a
percentage, setting the value of untreated cells (C) arbitrarily at 100%.
TNFα and IL-1β release, determined by ELISA assay, was expressed as % of untreated cells set equal to 100%.
Data are means ± S.D. of 4 experiments. For each protein (PPARα, TNFα or IL-1β) means with different letters are significantly different from one another
(p < 0.05) as determined by analysis of variance followed by a post-hoc Newman-Keuls test.
See legend in Fig. 2 for acronyms.
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